Xenaclin-V3 Softgel Capsule contains a combination of Clindamycin 100mg and Clotrimazole 200mg, formulated to provide effective treatment against mixed bacterial and fungal infections. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby exerting a bacteriostatic effect against susceptible aerobic and anaerobic gram-positive bacteria. Clotrimazole is an imidazole antifungal agent that disrupts the synthesis of ergosterol, an essential component of fungal cell membranes, leading to increased membrane permeability and cell death. Xenaclin-V3 is indicated for the management of infections where both bacterial and fungal pathogens are implicated, such as complicated skin and soft tissue infections, certain gynecological infections, and mixed oral infections. The softgel formulation enhances bioavailability and patient compliance. Administration should follow prescribed dosage regimens, and therapy duration depends on infection severity and clinical response. Caution is advised in patients with known hypersensitivity to clindamycin, clotrimazole, or other imidazoles. Potential adverse effects include gastrointestinal disturbances, allergic reactions, and, rarely, antibiotic-associated colitis. Use during pregnancy and lactation should be under medical supervision. Xenaclin-V3 Softgel Capsule should be stored in a cool, dry place, away from direct sunlight, and kept out of reach of children.